Aspire Biopharma Holdings Inc. has submitted a Pre-IND meeting request and briefing package to the U.S. Food and Drug Administration (FDA) for its lead product candidate, a fast-acting, high-dose sublingual aspirin formulation intended for the treatment of suspected acute myocardial infarction (heart attack). This submission marks an important step in seeking FDA guidance on the clinical development strategy and confirmation of the proposed 505(b)(2) regulatory pathway. No grant or funding involving Aspire or multiple organizations is mentioned.